Die Ophthalmologie最新文献_第10页

[Ectopia lentis]. [眼睑外翻]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-05-03 DOI: 10.1007/s00347-024-02044-2

Leoni Britz, Gerd Uwe Auffarth, Ramin Khoramnia

引用次数: 0

[Cell loss in retinal ischemia is associated with increased necroptosis]. [视网膜缺血时细胞丢失与坏死增加有关]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1007/s00347-024-02063-z

Teresa Tsai, Leonie Deppe, H Burkhard Dick, Stephanie C Joachim

{"title":"[Cell loss in retinal ischemia is associated with increased necroptosis].","authors":"Teresa Tsai, Leonie Deppe, H Burkhard Dick, Stephanie C Joachim","doi":"10.1007/s00347-024-02063-z","DOIUrl":"10.1007/s00347-024-02063-z","url":null,"abstract":"Background: Retinal ischemia plays a central pathophysiological role in numerous eye diseases, such as glaucoma. In addition to apoptosis, autophagy, necroptosis and ferroptosis are among the cell death mechanisms of ischemia; however, their role is not clearly understood and controversially discussed.Objective: The aim of this study is to gain an improved understanding of the role of alternative cell death mechanisms such as autophagy and necroptosis after retinal ischemia. Based on this, future autophagy-based or necroptosis-based therapeutic approaches could be developed.Material and methods: Retinal ischemia reperfusion was induced in one eye of 6 to 8‑week-old rats by temporarily increasing the intraocular pressure to 140 mm Hg (60 min), followed by reperfusion. The untreated contralateral eye served as a control. Retinas after ischemia and control retinas were examined 7 days after ischemia immunohistochemically with markers for retinal ganglion cells (RGC), astrocytes (GFAP) as well as an autophagy (LAMP1) and a necroptosis marker (RIPK3) (n = 6/group).Results: Ischemia reperfusion resulted in both significant RGC loss (p ≤ 0.001) and a significant increase of astrocyte area (p = 0.026) after 7 days. Interestingly, the number of autophagic LAMP1 positive cells was unchanged 7 days after ischemia (p = 0.272), whereas the number of necroptotic RIPK3 positive cells was significantly increased (p ≤ 0.001).Conclusion: Necroptotic processes appear to be activated 7 days after ischemia reperfusion, contributing to retinal cell death and activation of astrocytes. Late autophagic processes are not activated 7 days after ischemia. Necroptosis-associated parameters could therefore be targeted as an early therapeutic approach after ischemia in the future.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"644-649"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141452265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Uveitis and multiple sclerosis : Clinical aspects, diagnostics, management and treatment]. [葡萄膜炎和多发性硬化症：临床方面、诊断、管理和治疗]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-07-22 DOI: 10.1007/s00347-024-02084-8

Nicole Stübiger, Klemens Ruprecht, Uwe Pleyer

引用次数: 0

[Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept]. [阿弗利百普在真实世界中的应用：AURIGA 研究：视网膜静脉闭塞后黄斑水肿的德国治疗无效患者队列接受玻璃体内阿弗利百普治疗 24 个月的结果]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-07-08 DOI: 10.1007/s00347-024-02051-3

Joachim Wachtlin, Hakan Kaymak, Hans Hoerauf, Helmut Allmeier, Tobias Machewitz, Paula Scholz, Markus Schürks, Nicolas Feltgen

{"title":"[Aflibercept in a real-world setting: the AURIGA study : 24-month results of the German cohort of treatment-naïve patients with macular edema following retinal vein occlusion receiving intravitreal aflibercept].","authors":"Joachim Wachtlin, Hakan Kaymak, Hans Hoerauf, Helmut Allmeier, Tobias Machewitz, Paula Scholz, Markus Schürks, Nicolas Feltgen","doi":"10.1007/s00347-024-02051-3","DOIUrl":"10.1007/s00347-024-02051-3","url":null,"abstract":"Background: AURIGA is the largest prospective real-world study to evaluate intravitreal aflibercept 2 mg (IVT-AFL) treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) and diabetic macular edema. Here we present the 24-month data from the German cohort of treatment-naïve patients with ME due to RVO.Methods: Treatment-naïve patients with ME secondary to RVO were treated with IVT-AFL 2 mg in the routine clinical practice. The primary endpoint was mean change in visual acuity (VA, early treatment diabetic retinopathy, ETDRS, letters) at month 12 compared to baseline. Analyses were descriptive.Results: Analysis included 130 patients with RVO (n = 61, 46.9% with central RVO, n = 69, 53.1% with branch RVO). The mean (± SD) time the RVO patients remained in the study was 18.4 ± 7.4 months. The mean VA gain (95% confidence interval) in the overall cohort was +10.9 (7.5-14.2) letters at month 12 and +9.7 (6.1-13.3) at month 24 (baseline VA 56.5 ± 18.9 letters). At 24 months, 67% of RVO patients gained ≥5 letters and 40% gained ≥15 letters. The mean number of injections was 4.4 ± 1.3 up to month 6, 6.2 ± 2.7 up to month 12 and 8.2 ± 4.5 up to month 24. The mean central retinal thickness (CRT) reduction was -206µm (-252 to -160µm) at 12 months and -219µm (-263 to -175µm) at 24 months (baseline CRT 507 ± 177 µm). The safety profile was consistent with that of previous studies.Discussion: In the German AURIGA cohort of treatment-naïve patients with ME secondary to RVO, IVT-AFL 2 mg treatment in clinical practice resulted in rapid and clinically relevant VA gains and a reduction in CRT. These results were largely maintained over 24 months despite the low injection frequency from month 6.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"650-657"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Vital appearing residual tumor of a choroidal melanoma after proton irradiation]. [质子辐照后脉络膜黑色素瘤的残留肿瘤]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-06-21 DOI: 10.1007/s00347-024-02060-2

Lukas Schloesser, Karin U Loeffler, Thomas Ach, Martina C Herwig-Carl

引用次数: 0

[Click phenomenon in acquired Jaensch-Brown syndrome and trigger finger/thumb: the Notta syndrome]. [获得性詹施-布朗综合征和扳机指/拇指的点击现象：诺塔综合征]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1007/s00347-024-02059-9

Hermann Mühlendyck

{"title":"[Click phenomenon in acquired Jaensch-Brown syndrome and trigger finger/thumb: the Notta syndrome].","authors":"Hermann Mühlendyck","doi":"10.1007/s00347-024-02059-9","DOIUrl":"10.1007/s00347-024-02059-9","url":null,"abstract":"Clinical features: The click phenomenon occurs when an acquired mechanical restriction of the elevation in adduction of the eye or of the extension of the finger/thumb, is forcefully overcome. The common cause is a nodule either of the superior oblique tendon posterior to the trochlea in the case of a Jaensch-Brown syndrome or of the digital flexor tendon anterior to the A1 annular pulley in the case of a trigger finger. Both locations share similar anatomical conditions for the development of the nodule and the pathomechanism of the click.Results: From these identical findings in the eye and the hand in small children it can be assumed that the results from the studies of the hand in newborns and infants with a trigger thumb/finger are also applicable to the situation of the eye. 1. This motility disorder is not congenital. This is most likely due to an incomplete development at the time of birth of the sliding factors needed for a free passage of the tendon through the trochlea and the A1 annular pulley. 2. A distinction must be made between stages 0-3: stage 0 = no more restriction of the motility and no click phenomenon; stage 1 = forced active extension/elevation possible; stage 2 = only passive extension/elevation, each with a click phenomenon; stage 3 = no extension/elevation possible and no click phenomenon. 3. In most cases in early childhood there is a spontaneous complete recovery (75% after 6-7 years). In the eye this spontaneous course can only limitedly be shortened with motility exercises in combination with segmental occlusion.Conclusion: The click phenomenon is a symptom of stages 1 and 2 of an acquired mechanical restriction of the elevation in adduction of the eye or the extension of the finger/thumb. It should not be called a syndrome.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"631-643"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Use of artificial intelligence for recognition of biomarkers in intermediate age-related macular degeneration]. [利用人工智能识别中老年黄斑变性的生物标志物]。

Die Ophthalmologie Pub Date : 2024-08-01 Epub Date: 2024-07-31 DOI: 10.1007/s00347-024-02078-6

Leon von der Emde, Sandrine H Künzel, Maximilian Pfau, Olivier Morelle, Yannick Liermann, Petrus Chang, Kristina Pfau, Sarah Thiele, Frank G Holz

{"title":"[Use of artificial intelligence for recognition of biomarkers in intermediate age-related macular degeneration].","authors":"Leon von der Emde, Sandrine H Künzel, Maximilian Pfau, Olivier Morelle, Yannick Liermann, Petrus Chang, Kristina Pfau, Sarah Thiele, Frank G Holz","doi":"10.1007/s00347-024-02078-6","DOIUrl":"10.1007/s00347-024-02078-6","url":null,"abstract":"Advances in imaging and artificial intelligence (AI) have revolutionized the detection, quantification and monitoring for the clinical assessment of intermediate age-related macular degeneration (iAMD). The iAMD incorporates a broad spectrum of manifestations, which range from individual small drusen, hyperpigmentation, hypopigmentation up to early stages of geographical atrophy. Current high-resolution imaging technologies enable an accurate detection and description of anatomical features, such as drusen volumes, hyperreflexive foci and photoreceptor degeneration, which are risk factors that are decisive for prediction of the course of the disease; however, the manual annotation of these features in complex optical coherence tomography (OCT) scans is impractical for the routine clinical practice and research. In this context AI provides a solution by fully automatic segmentation and therefore delivers exact, reproducible and quantitative analyses of AMD-related biomarkers. Furthermore, the application of AI in iAMD facilitates the risk assessment and the development of structural endpoints for new forms of treatment. For example, the quantitative analysis of drusen volume and hyperreflective foci with AI algorithms has shown a correlation with the progression of the disease. These technological advances therefore improve not only the diagnostic precision but also support future targeted treatment strategies and contribute to the prioritized target of personalized medicine in the diagnostics and treatment of AMD.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":"609-615"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141857285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum zu: Abstractband DOG 2023. 勘误：摘要卷 DOG 2023。

Die Ophthalmologie Pub Date : 2024-07-30 DOI: 10.1007/s00347-024-02086-6

引用次数: 0

Erratum zu: Makulaschichtforamen – im Zentrum der vitreomakulären Grenzflächenerkrankungen. 黄斑层孔--玻璃体-黄斑界面疾病的中心。

Die Ophthalmologie Pub Date : 2024-07-04 DOI: 10.1007/s00347-024-02070-0

Julian E Klaas, Albrecht Lommatzsch, Tim U Krohne, Lars-Olof Hattenbach, Siegfried Priglinger

引用次数: 0

[Liquefied after-cataract]. [液化后霰粒肿]。

Die Ophthalmologie Pub Date : 2024-07-04 DOI: 10.1007/s00347-024-02077-7

Katharina Fabian, Lucy J Kessler, Victor A Augustin, Gerd U Auffarth, Ramin Khoramnia

引用次数: 0